CAVH를 이용하여 치료한 비신장성 질환

• Published in: Kidney research and clinical practice Vol. 17; no. 3; pp. 476 - 482
• Main Authors: 이인상, 박정현, 이인태, 김치학
• Format: Journal Article
• Language: Korean
• Published: 대한신장학회 30.05.1998
• ISSN: 2211-9132

Continuous arteriovenous hemofiltration(CAVH) is used to treat hemodynamically unstable patients with renal failure, refractory ascites and edema, sepsis, or ARDS patients. Patients received CAVH during a 3-year-period from March 1994 to February 1997. Their clinical findings were analyzed retrospectively, and the results were as follows', They were 6 men and 3 women from 28 to 62 years. 3 patients had ARDS, 2 patients had CHF. The remainder had SLE, liver cirrhosis, septic shock with cholangitis, diabetic ketoacidosis with pulmo- nary edema. The duration of treatment ranged from 30 to 50 hours, with a mean of 41.6±6.9 hours. The total fluid repalcernent was 22.4±1.7L and the mean fluid loss was 3.9±2.6L. Changes in serum BUN, creatinine, sodium, potasium before and after treat- ment were not significantly different. The compli- cation of CAVH is clotting of hemofilter, hypoten- sion, bleeding, and mild thrombocytopenia. 2 of 3 ARDS patients expired during CAVH, liver cirrhosis patient expired later due to hepatic encephalopathy, and, finally 6 patients discharged with improved conditions. In conclusion, CAVH, a safe and effective therapy in hemodynamically unstable patients with renal failure, refractory ascites and edema, sepsis, or ARDS patients.